Walter A Kukull

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1802495/publications.pdf

Version: 2024-02-01

161 papers 30,803 citations

68 h-index 7496 151 g-index

162 all docs

 $\begin{array}{c} 162 \\ \\ \text{docs citations} \end{array}$

times ranked

162

30611 citing authors

#	Article	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
3	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	9.4	1,676
4	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
5	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
6	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
7	Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. Journal of Neuropathology and Experimental Neurology, 2012, 71, 266-273.	0.9	797
8	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
9	The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer Disease and Associated Disorders, 2006, 20, 210-216.	0.6	743
10	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
11	The Alzheimer's Disease Centers' Uniform Data Set (UDS). Alzheimer Disease and Associated Disorders, 2009, 23, 91-101.	0.6	684
12	Dementia and Alzheimer Disease Incidence. Archives of Neurology, 2002, 59, 1737.	4.9	668
13	Exercise Plus Behavioral Management in Patients With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2015.	3.8	653
14	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain, 2013, 136, 2697-2706.	3.7	609
15	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 2009, 30, 1026-1036.	1.5	558
16	The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set. Alzheimer Disease and Associated Disorders, 2007, 21, 249-258.	0.6	557
17	Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4441-4446.	3.3	529
18	Depression as a Risk Factor for Alzheimer Disease. Archives of Neurology, 2003, 60, 753.	4.9	485

#	Article	IF	Citations
19	GAB2 Alleles Modify Alzheimer's Risk in APOE É>4 Carriers. Neuron, 2007, 54, 713-720.	3.8	451
20	Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Archives of Neurology, 2010, 67, 1473.	4.9	376
21	Variants in the ATP-Binding Cassette Transporter (ABCA7), Apolipoprotein E ϵ4, and the Risk of Late-Onset Alzheimer Disease in African Americans. JAMA - Journal of the American Medical Association, 2013, 309, 1483.	3.8	360
22	Clinicoâ€Neuropathological Correlation of Alzheimer's Disease in a Communityâ€Based Case Series. Journal of the American Geriatrics Society, 1999, 47, 564-569.	1.3	354
23	Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Disease and Associated Disorders, 2018, 32, 10-17.	0.6	337
24	Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLoS Medicine, 2017, 14, e1002258.	3.9	311
25	National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's and Dementia, 2011, 7, 61-73.	0.4	305
26	Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. PLoS Genetics, 2014, 10, e1004606.	1.5	305
27	APOE Ϊμ4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	4.5	302
28	Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiological Genomics, 2007, 28, 311-322.	1.0	277
29	Progression to dementia in patients with isolated memory loss. Lancet, The, 1997, 349, 763-765.	6.3	268
30	Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiological Genomics, 2008, 33, 240-256.	1.0	264
31	Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications, 2020, 11, 667.	5.8	246
32	Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Disease and Associated Disorders, 2018, 32, 351-358.	0.6	241
33	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurology, 2018, 75, 989.	4.5	223
34	Characteristics of Sleep Disturbance in Community-Dwelling Alzheimer's Disease Patients. Journal of Geriatric Psychiatry and Neurology, 1999, 12, 53-59.	1.2	218
35	Subjective Memory Deterioration and Future Dementia in People Aged 65 and Older. Journal of the American Geriatrics Society, 2004, 52, 2045-2051.	1.3	198
36	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198

#	Article	IF	Citations
37	Generalizability. Neurology, 2012, 78, 1886-1891.	1.5	182
38	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, $2015,11,658-671.$	0.4	173
39	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
40	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
41	Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1359-1371.	1.5	158
42	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
43	Footwear Style and Risk of Falls in Older Adults. Journal of the American Geriatrics Society, 2004, 52, 1495-1501.	1.3	152
44	Symptom Patterns and Comorbidity in the Early Stages of Alzheimer's Disease. Journal of the American Geriatrics Society, 1994, 42, 517-521.	1.3	138
45	<i>GBA</i> mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 2012, 79, 1944-1950.	1.5	138
46	Neighborhood Environment and Cognition in Older Adults: A Systematic Review. American Journal of Preventive Medicine, 2017, 53, 241-251.	1.6	138
47	Clinical and Neuropathological Characteristics of Hippocampal Sclerosis. Archives of Neurology, 2002, 59, 1099.	4.9	136
48	Biomechanical Properties of Shoes and Risk of Falls in Older Adults. Journal of the American Geriatrics Society, 2004, 52, 1840-1846.	1.3	125
49	Body Mass Index, Weight Change, and Clinical Progression in Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2014, 28, 36-43.	0.6	122
50	Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Movement Disorders, 2006, 21, 964-969.	2.2	118
51	Age-Varying Association Between Blood Pressure and Risk of Dementia in Those Aged 65 and Older: A Community-Based Prospective Cohort Study. Journal of the American Geriatrics Society, 2007, 55, 1161-1167.	1.3	117
52	The Revised National Alzheimer's Coordinating Center's Neuropathology Form—Available Data and New Analyses. Journal of Neuropathology and Experimental Neurology, 2018, 77, 717-726.	0.9	116
53	Using Census Data and Birth Certificates to Reconstruct the Early-Life Socioeconomic Environment and the Relation to the Development of Alzheimer's Disease. Epidemiology, 2001, 12, 383-389.	1.2	113
54	Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes. Neurobiology of Aging, 2015, 36, 2702-2708.	1.5	108

#	Article	IF	CITATIONS
55	RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewyâ€Related Pathology in the Dementia Patient. Brain Pathology, 2008, 18, 220-224.	2.1	106
56	EPIDEMIOLOGY OF DEMENTIA. Neurologic Clinics, 2000, 18, 923-949.	0.8	97
57	Two rare <i>AKAP9</i> variants are associated with Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2014, 10, 609.	0.4	94
58	Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. Neurobiology of Aging, 2011, 32, 2113-2122.	1.5	93
59	Ageâ€Varying Association Between Statin Use and Incident Alzheimer's Disease. Journal of the American Geriatrics Society, 2010, 58, 1311-1317.	1.3	88
60	Two novel loci, <i>COBL</i> and <i>SLC10A2</i> , for Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2017, 13, 119-129.	0.4	87
61	Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
62	Dementia epidemiology. Medical Clinics of North America, 2002, 86, 573-590.	1.1	84
63	Hippocampal Sclerosis of Aging is a Key Alzheimer's Disease Mimic: Clinical-Pathologic Correlations and Comparisons with both Alzheimer's Disease and Non-Tauopathic Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2014, 39, 691-702.	1.2	83
64	Tumor Necrosis Factor $\hat{I}\pm$ and Interleukin 10 Promoter Region Polymorphisms and Risk of Late-Onset Alzheimer Disease. Archives of Neurology, 2006, 63, 1165.	4.9	79
65	Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques. JAMA Neurology, 2015, 72, 1124.	4.5	78
66	Sleep Disturbance in Dementia with Lewy Bodies and Alzheimer's Disease: A Multicenter Analysis. Dementia and Geriatric Cognitive Disorders, 2011, 31, 239-246.	0.7	75
67	Neuropathologic differences by race from the National Alzheimer's Coordinating Center. Alzheimer's and Dementia, 2016, 12, 669-677.	0.4	75
68	Associations between depression, sleep disturbance, and apolipoprotein E in the development of Alzheimer's disease: dementia. International Psychogeriatrics, 2016, 28, 1409-1424.	0.6	74
69	Healthcare Utilization and Costs in Managed Care Patients with Alzheimer's Disease During the Last Few Years of Life. Journal of the American Geriatrics Society, 2001, 49, 1156-1160.	1.3	72
70	Symptom Distress, Psychosocial Variables, and Survival From Lung Cancer. Journal of Psychosocial Oncology, 1986, 4, 91-104.	0.6	71
71	ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathologica, 2014, 127, 825-843.	3.9	70
72	The human FE65 gene: genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type. Human Genetics, 1998, 103, 295-303.	1.8	68

#	Article	IF	Citations
73	Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiology of Aging, 2010, 31, 549-566.	1.5	68
74	Impact of Sample Selection on APOE \hat{a}^4 Allele Frequency: A Comparison of Two Alzheimer's Disease Samples. Journal of the American Geriatrics Society, 1996, 44, 704-707.	1.3	67
75	Sex differences in the genetic predictors of Alzheimer's pathology. Brain, 2019, 142, 2581-2589.	3.7	65
76	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
77	Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinicand community-based samples. Neurobiology of Aging, 2017, 53, 83-92.	1.5	64
78	Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center. Alzheimer's and Dementia, 2019, 15, 1533-1545.	0.4	64
79	Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration. Brain, 2019, 142, 460-470.	3.7	63
80	The association between smoking and Alzheimer's disease: effects of study design and bias. Biological Psychiatry, 2001, 49, 194-199.	0.7	61
81	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology, 2014, 83, 434-440.	1.5	61
82	Associations Between Microinfarcts and Other Macroscopic Vascular Findings on Neuropathologic Examination in 2 Databases. Alzheimer Disease and Associated Disorders, 2009, 23, 291-294.	0.6	54
83	Apolipoprotein E in Alzheimer's disease risk and case detection: A case-control study. Journal of Clinical Epidemiology, 1996, 49, 1143-1148.	2.4	52
84	Reassessment of Risk Genotypes (<i>GRN</i> , <i>TMEM106B</i> , and <i>ABCC9</i> Variants) Associated With Hippocampal Sclerosis of Aging Pathology. Journal of Neuropathology and Experimental Neurology, 2015, 74, 75-84.	0.9	50
85	Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology, 2013, 80, 2121-2129.	1.5	49
86	Polygenic hazard scores in preclinical Alzheimer disease. Annals of Neurology, 2017, 82, 484-488.	2.8	49
87	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
88	Challenges and Considerations Related to Studying Dementia in Blacks/African Americans. Journal of Alzheimer's Disease, 2017, 60, 1-10.	1.2	48
89	Comparison of symptomatic and asymptomatic persons with primary age-related tauopathy. Neurology, 2017, 89, 1707-1715.	1.5	47
90	Sex-dependent autosomal effects on clinical progression of Alzheimer's disease. Brain, 2020, 143, 2272-2280.	3.7	46

#	Article	IF	CITATIONS
91	The cognitive abilities screening instrument (CASI): data from a cohort of 2524 cognitively intact elderly., 1999, 14, 882-888.		44
92	Global and local ancestry in Africanâ€Americans: Implications for Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 233-243.	0.4	42
93	Calcium channel blockers and \hat{l}^2 -blockers in relation to Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, 165-169.	1.1	41
94	Rarity of the Alzheimer Disease–Protective <i>APP</i> A673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
95	Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer's disease and cerebrovascular disease pathologies. Acta Neuropathologica Communications, 2018, 6, 142.	2.4	41
96	Neighborhood built environment and cognition in non-demented older adults: The Multi-Ethnic Study of Atherosclerosis. Social Science and Medicine, 2018, 200, 27-35.	1.8	40
97	Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurology, 2015, 72, 1313.	4.5	39
98	Similarities and Differences in Attitudes Toward Long-Term Care Between Japanese Americans and Caucasian Americans. Journal of the American Geriatrics Society, 2002, 50, 1149-1155.	1.3	38
99	Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Archives of Gerontology and Geriatrics, 2016, 65, 231-238.	1.4	38
100	Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course. Journal of Neurology, 2020, 267, 2941-2948.	1.8	38
101	Intracellular calcium response is reduced in CD4+ lymphocytes in Alzheimer's disease and in older persons with down's syndrome. Neurobiology of Aging, 1993, 14, 177-185.	1.5	37
102	A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy. JAMA Neurology, 2015, 72, 414.	4.5	37
103	Conjugal Alzheimer Disease. Archives of Neurology, 2008, 65, 373-8.	4.9	37
104	Medical complications of ischemic stroke and length of hospital stay: Experience in Seattle, Washington. Journal of Stroke and Cerebrovascular Diseases, 1999, 8, 336-343.	0.7	36
105	Cognitive trajectory in mild cognitive impairment due to primary age-related tauopathy. Brain, 2020, 143, 611-621.	3.7	36
106	Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010., 2011, 7, 127-132.		35
107	Differences in rate of functional decline across three dementia types. Alzheimer's and Dementia, 2013, 9, S63-71.	0.4	34
108	Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism and Related Disorders, 2014, 20, 503-507.	1.1	34

#	Article	IF	CITATIONS
109	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
110	Thinking Outside the Box: Alzheimer-Type Neuropathology That Does Not Map Directly Onto Current Consensus Recommendations. Journal of Neuropathology and Experimental Neurology, 2010, 69, 449-454.	0.9	33
111	Future prospects and challenges for Alzheimer's disease drug development in the era of the NIAâ€AA Research Framework. Alzheimer's and Dementia, 2018, 14, 532-534.	0.4	33
112	The effect of diagnosing Alzheimer's disease on frequency of physician visits. Journal of General Internal Medicine, 1995, 10, 187-193.	1.3	32
113	Population Neuroscience. Alzheimer Disease and Associated Disorders, 2018, 32, 1-9.	0.6	32
114	Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy. American Journal of Geriatric Psychiatry, 2009, 17, 317-323.	0.6	29
115	Theoretical Impact of Florbetapir (¹⁸ F) Amyloid Imaging on Diagnosis of Alzheimer Dementia and Detection of Preclinical Cortical Amyloid. Journal of Neuropathology and Experimental Neurology, 2014, 73, 948-953.	0.9	29
116	Differences in Cognitive Impairment in Primary Age-Related Tauopathy Versus Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2019, 78, 219-228.	0.9	29
117	Decreasing hazards of <scp>Alzheimer</scp> 's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein <scp>E</scp> . International Journal of Geriatric Psychiatry, 2018, 33, 200-211.	1.3	27
118	Risk of dementia and mild cognitive impairment among older adults in sameâ€sex relationships. International Journal of Geriatric Psychiatry, 2019, 34, 828-835.	1.3	27
119	Mitochondrial Genetic Variants and Alzheimer Disease: A Case-Control Study of the T4336C and G5460A Variants. Alzheimer Disease and Associated Disorders, 2002, 16, 1-7.	0.6	26
120	Magnetic resonance imaging brain atrophy assessment in primary age-related tauopathy (PART). Acta Neuropathologica Communications, 2019, 7, 204.	2.4	25
121	<i>APOE</i> is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort. Neurology, 2020, 94, e607-e612.	1.5	25
122	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. Alzheimer's and Dementia, 2020, 16, 589-597.	0.4	25
123	Active and Passive Cigarette Smoking and Risk of Intracranial Meningioma. Neuroepidemiology, 2005, 24, 117-122.	1.1	24
124	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.4	24
125	Older Adults and Functional Decline: A Cross-Cultural Comparison. International Psychogeriatrics, 2002, 14, 161-179.	0.6	23
126	Enhancing the Power of Genetic Association Studies through the Use of Silver Standard Cases Derived from Electronic Medical Records. PLoS ONE, 2013, 8, e63481.	1.1	23

#	Article	IF	Citations
127	Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. Journal of Neuropathology and Experimental Neurology, 2016, 75, 955-962.	0.9	23
128	Clinical diagnoses among individuals with primary age-related tauopathy versus Alzheimer's neuropathology. Laboratory Investigation, 2019, 99, 1049-1055.	1.7	23
129	Lost in Translation. Archives of Neurology, 2010, 67, 107-11.	4.9	21
130	Mixed neuropathologies and associations with domain-specific cognitive decline. Neurology, 2017, 89, 1773-1781.	1.5	21
131	Associations between neighborhood built environment and cognition vary by apolipoprotein E genotype: Multi-Ethnic Study of Atherosclerosis. Health and Place, 2019, 60, 102188.	1.5	21
132	Limbic-Predominant Age-Related TDP-43 Encephalopathy. Neurology, 2022, 98, .	1.5	21
133	Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 195-201.	1.2	20
134	Social Relationships and Risk of Incident Mild Cognitive Impairment in US Alzheimer's Disease Centers. Alzheimer Disease and Associated Disorders, 2014, 28, 253-260.	0.6	19
135	FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer's disease. Acta Neuropathologica, 2022, 144, 59-79.	3.9	19
136	Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy. Journal of Neuropathology and Experimental Neurology, 2020, 79, 465-473.	0.9	17
137	Big data, aging, and dementia: Pathways for international harmonization on data sharing. , 2013, 9, S61-S62.		16
138	Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiology of Aging, 2018, 62, 64-71.	1.5	16
139	Comparing measures of decline to dementia in amnestic MCI subjects in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set. International Psychogeriatrics, 2012, 24, 1553-1560.	0.6	15
140	Episodic memory performance in a multi-ethnic longitudinal study of 13,037 elderly. PLoS ONE, 2018, 13, e0206803.	1.1	15
141	Role of brain infarcts in behavioral variant frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2861-2868.	1.5	14
142	Distinguishing Alzheimer's Disease from Other Dementias. Journal of the American Geriatrics Society, 1989, 37, 521-527.	1.3	13
143	Risk of mild cognitive impairment among older adults in the United States by ethnoracial group. International Psychogeriatrics, 2021, 33, 51-62.	0.6	13
144	Differences in Symptomatic Presentation and Cognitive Performance Among Participants With LATE-NC Compared to FTLD-TDP. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1024-1032.	0.9	13

#	Article	IF	CITATIONS
145	Progranulin mutations in clinical and neuropathological Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 2458-2467.	0.4	12
146	Risk of Decline in Functional Activities in Dementia With Lewy Bodies and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2011, 25, 17-23.	0.6	11
147	Clinical and Surgical Factors Associated With Increased Epilepsy Risk in Children With Hydrocephalus. Pediatric Neurology, 2016, 59, 18-22.	1.0	11
148	Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease. Neurology, 2022, 98, .	1.5	10
149	Comparison of Alzheimer's disease in American Indians, whites, and African Americans. , 2007, 3, 211-216.		9
150	The growing global burden of dementia. Lancet Neurology, The, 2006, 5, 199-200.	4.9	8
151	Cognitive Impairment in Older Adults Without Dementia: Clinical and Pathologic Outcomes in a Community-Based Sample. Journal of Geriatric Psychiatry and Neurology, 2009, 22, 256-265.	1.2	8
152	Interrater Reliability and Accuracy in Identifying Ischemic Strokes Using Computed Tomography Scans in People with Dementia. Journal of the American Geriatrics Society, 2005, 53, 1743-1747.	1.3	7
153	The Nevada Vital Aging Initiative: A private-public partnership to study early predictors of dementia. , 2007, 3, 62-67.		7
154	An apple a day to prevent Parkinson disease. Neurology, 2012, 78, 1112-1113.	1.5	7
155	APOE Polymorphisms and Late-Onset Alzheimer Disease. JAMA - Journal of the American Medical Association, 1998, 279, 788.	3.8	4
156	Neuropathological lesions and their contribution to dementia and cognitive impairment in a heterogeneous clinical population. Alzheimer's and Dementia, 2022, 18, 2403-2412.	0.4	4
157	The cognitive abilities screening instrument (CASI): data from a cohort of 2524 cognitively intact elderly., 1999, 14, 882.		3
158	The Alzheimer's Disease Centers' Neuropsychological Database Initiative: A Resource for Alzheimer's Disease Prevention Trials., 0,, 129-140.		0
159	Perspectives on Shared Genetic Contributions for Parkinson Disease and Alzheimer Disease. Archives of Neurology, 2004, 61, 1007-8.	4.9	0
160	Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.―"Big Asks― What can be changed to increase and speed progress on Alzheimer's disease research and treatment?. , 2009, 5, 137-139.		0
161	Alzheimer's Disease and the Search for Environmental Risk Factors. , 2015, , 315-327.		O